

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

## Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/582,014
Filing Date	June 7, 2006
First Named Inventor	Takeshi Kuroda et al.
Art Unit	To be Assigned
Examiner Name	To be Assigned
Attorney Docket Number	4676-237

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-3,152,905	10-13-64	Bela Gaspar	
		US-3,427,310	02-11-69	Bela Gaspar	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 2004/064860 A1	08-05-2004	Cincinnati Children's Hospital Medical Center		
		WO 2004/028535 A1	04-08-2004	Pintex Pharmaceuticals, Inc.		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>5</sup>
		PIA AZARSHAB ET AL., "Aspirin promotes TFF2 gene activation in human gastric cancer cell lines," <i>FEBS Letters</i> , (2001), Vol. 488, No. 3, pp. 206-210	
		A. KOITABASHI ET AL., "Indometacin up-regulates TFF2 expression in gastric epithelial cells," (July 2004), Vol. 20, Suppl. 1, PP. 171-176	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1187043\_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>CORRECTED</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/582,014
		Filing Date	June 7, 2006
		First Named Inventor	Takeshi Kuroda et al.
		Art Unit	To be Assigned
		Examiner Name	To be Assigned
		Attorney Docket Number	4676-237
Sheet	1	of	2

### U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			

**Note:** Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 92/14837 A1	09-03-92	The General Hospital Corporation		
		WO 02/102403 A1	12-27-02	Novo Nordisk A/S		
		WO 02/46226 A2	06-13-02	Novo Nordisk A/S		
		WO 01/02377 A1	01-11-01	Geron Corporation; Kyowa Hakko Kogyo Co., Ltd.		
		WO 02/051409 A1	07-04-02	Geron Corporation; Kyowa Hakko Kogyo Co., Ltd.		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		DOUGLAS TAUPIN ET AL., "Trefol Factors: Initiators of Mucosal Healing," <i>Nature Reviews/Molecular Cell Biology</i> , (2003), Vol. 4, pp. 721-732	
		RAYMOND J. PLAYFORD ET AL., "Human Spasmolytic Polypeptide Is a Cytoprotective Agent That Stimulates Cell Migration," <i>Gastroenterology</i> , (1995), Vol. 108, pp. 108-116	
		MARK W. BABYATSKY ET AL., "Oral Trefol Peptides Protect Against Ethanol- and Indomethacin-Induced Gastric Injury in Rats," <i>Gastroenterology</i> , (1996), Vol. 110, pp. 489-497	
		C. MCKENZIE ET AL., "Topical and Intravenous administration of trefol factors protect the gastric mucosa from ethanol-induced injury in the rat," <i>Alim. Pharmacol. Ther.</i> , (2000), Vol. 14, pp. 1033-1040	
		S. S. POULSEN ET AL., "Metabolism of oral trefol factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat," <i>Gut</i> , (1999), Vol. 45, pp. 516-522	
		C. P. TRAN ET AL., "Trefol peptide TFF2 (spasmolytic polypeptide) potentially accelerates healing and reduces inflammation in a rat model of colitis," <i>Gut</i> , (1999), Vol. 44, pp. 636-642	
		ANTONIO SORIANO-IZQUIERDO ET AL., "Trefol peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation," <i>J. Leukoc. Biol.</i> , (2004), Vol. 75, pp. 214-223	
		JAMES J. FARRELL, "TFFS/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury," <i>J. Clin. Invest.</i> , (2002), Vol. 109, pp. 193-204	
		L. THIM ET AL., "Effect of trefol factors on the viscoelastic properties of mucus gels," <i>Eur. J. Clin. Invest.</i> , (2002), Vol. 32, pp. 519-527	
		NIKOLAOS M. NIKOLAIDIS ET AL., "Trefol factor-2 is an Allergen-Induced Gene Regulated by Th2 Cytokines and STAT6 in the Lung," <i>Am. J. Respir. Cell Mol. Biol.</i> , (2003), Vol. 29, pp. 458-464	
		P. L. BECK ET AL., "Chemotherapy- and Radiotherapy-Induced Intestinal Damage Is Regulated by Intestinal Trefol Factor," <i>Gastroenterology</i> , (2004), Vol. 126, pp. 796-808	
		OLIVIER LEFEBVRE ET AL., "Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the pS2 Trefol Protein," <i>Science</i> , (1996), Vol. 274, pp. 259-262	
		WON SANG PARK ET AL., "Somatic Mutations of the Trefol Factor Family 1 Gene in Gastric Cancer," <i>Gastroenterology</i> , (2000), Vol. 119, pp. 691-698	
		MASARU KATOH, "Trefol factors and human gastric cancer (Review)," <i>Int. J. Mol. Med.</i> , (2003), Vol. 12, pp. 3-9	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>CORRECTED INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<i>Application Number</i>	10/582,014
				<i>Filing Date</i>	June 7, 2006
				<i>First Named Inventor</i>	Takeshi Kuroda et al.
				<i>Art Unit</i>	To be Assigned
				<i>Examiner Name</i>	To be Assigned
<i>Sheet</i>	2	of	2	<i>Attorney Docket Number</i>	4676-237

NON PATENT LITERATURE DOCUMENTS		
	T. SHIMADA ET AL., "Up-regulation of TFF expression by PPAR $\gamma$ ligands in gastric epithelial cells," <i>Alim. Pharmacol. Ther.</i> , (2003), Vol. 18 (suppl. 1), pp. 119-125	
	TADAHITO SHIMADA, "PPAR $\gamma$ mediates NSAIDs-induced upregulation of TFF2 expression in gastric epithelial cells," <i>FEBS Lett.</i> , (2004), Vol. 558, pp. 33-38	
	TAKUJI TANAKA ET AL., "Ligands for Peroxisome Proliferator-activated Receptors $\alpha$ and $\gamma$ Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats <sup>1</sup> ," <i>Can. Res.</i> , (2001), Vol. 61, pp. 2424-2428	
	CONCEPCIÓN FERNÁNDEZ-ESTIVARIZ, "Trefol peptide expression and goblet cell number in rat intestine: effects of KGF and fasting-refeeding," <i>Am. J. Physiol. Regul. Integr. Comp. Physiol.</i> , (2003), Vol. 84, pp. R564-R573	

<i>Examiner Signature</i>	/D Margaret Seaman/	<i>Date Considered</i>	07/31/2009
---------------------------	---------------------	------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1187131\_1